Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

References

• BarnesPJWoolcockAJDifficult asthmaEur Respir J1998125120912189864023
   PubMed Web of Science ®Google Scholar
• DoughertyRHFahyJVAcute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotypeClin Exp Allergy200939219320219187331
   PubMed Web of Science ®Google Scholar
• LevyMLThe national review of asthma deaths: what did we learn and what needs to change?Breathe (Sheff)2015111142426306100
   PubMedGoogle Scholar
• HoustonJCDe NavasquezSTrounceJRA clinical and pathological study of fatal cases of status asthmaticusThorax19538320721313102418
   PubMed Web of Science ®Google Scholar
• HuberHLKoesslerKThe pathology of fatal asthmaArch Intern Med192230689760
   Google Scholar
• HamidQAzzawiMYingSExpression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthmaJ Clin Invest1991875154115462022726
   PubMed Web of Science ®Google Scholar
• YingSHumbertMBarkansJExpression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmaticsJ Immunol19971587353935449120316
   PubMed Web of Science ®Google Scholar
• WalkerCBodeEBoerLHanselTTBlaserKVirchowJCJAllergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavageAm Rev Respir Dis199214611091151626792
   PubMed Web of Science ®Google Scholar
• WardlawAJDunnetteSGleichGJCollinsJVKayABEosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivityAm Rev Respir Dis1988137162692447813
   PubMed Web of Science ®Google Scholar
• BousquetJChanezPLacosteJYEosinophilic inflammation in asthmaN Engl J Med199032315103310392215562
   PubMed Web of Science ®Google Scholar
• HornBRRobinEDTheodoreJVan KesselATotal eosinophil counts in the management of bronchial asthmaN Engl J Med197529222115211551124105
   PubMed Web of Science ®Google Scholar
• GibsonPGDolovichJGirgis-GabardoAThe inflammatory response in asthma exacerbation: changes in circulating eosinophils, basophils and their progenitorsClin Exp Allergy19902066616682083406
   PubMed Web of Science ®Google Scholar
• PizzichiniMMPizzichiniEClellandLSputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatmentAm J Respir Crit Care Med19971555150115089154849
   PubMed Web of Science ®Google Scholar
• van LeeuwenBHMartinsonMEWebbGCYoungIGMolecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5Blood1989735114211482564789
   PubMed Web of Science ®Google Scholar
• StraumannAConusSGrzonkaPAnti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trialGut2010591213019828470
   PubMed Web of Science ®Google Scholar
• GevaertPVan BruaeneNCattaertTMepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposisJ Allergy Clin Immunol20111285988989
   Web of Science ®Google Scholar
• RothenbergMEKlionADRoufosseFEMepolizumab HES Study GroupTreatment of patients with the hypereosinophilic syndrome with mepolizumabN Engl J Med2008358121215122818344568
   PubMed Web of Science ®Google Scholar
• KimSMarigowdaGOrenEIsraelEWechslerMEMepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndromeJ Allergy Clin Immunol201012561336134320513524
   PubMed Web of Science ®Google Scholar
• PlötzS-GSimonH-UDarsowUUse of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitisN Engl J Med2003349242334233914668459
   PubMed Web of Science ®Google Scholar
• SandersonCJEosinophil differentiation factor (interleukin-5)Immunol Ser1990492312562090253
   PubMedGoogle Scholar
• NussbaumJCVan DykenSJvon MoltkeJType 2 innate lymphoid cells control eosinophil homeostasisNature2013502747024524824037376
   PubMed Web of Science ®Google Scholar
• KolbeckRKozhichAKoikeMMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJ Allergy Clin Immunol2010125613441353.e220513525
   PubMed Web of Science ®Google Scholar
• HartTKCookRMZia-AmirhosseiniPPreclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysJ Allergy Clin Immunol2001108225025711496242
   PubMed Web of Science ®Google Scholar
• Flood-PagePTMenzies-GowANKayABRobinsonDSEosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airwayAm J Respir Crit Care Med2003167219920412406833
   PubMed Web of Science ®Google Scholar
• Menzies-GowAFlood-PagePSehmiRBurmanJHamidQRobinsonDSAnti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmaticsJ Allergy Clin Immunol2003111471471912704348
   PubMed Web of Science ®Google Scholar
• Flood-PagePMenzies-GowAPhippsSAnti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmaticsJ Clin Invest200311271029103614523040
   PubMed Web of Science ®Google Scholar
• LeckieMJTen BrinkeAKhanJEffects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic responseLancet200035692482144214811191542
   PubMed Web of Science ®Google Scholar
• KipsJCO’ConnorBJLangleySJEffect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot studyAm J Respir Crit Care Med2003167121655165912649124
   PubMed Web of Science ®Google Scholar
• BentleyAMHamidQRobinsonDSPrednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosaAm J Respir Crit Care Med199615325515568564096
   PubMed Web of Science ®Google Scholar
• BarnesPJHow corticosteroids control inflammation: Quintiles Prize Lecture 2005Br J Pharmacol2006148324525416604091
   PubMed Web of Science ®Google Scholar
• BarnesPJMechanisms of action of glucocorticoids in asthmaAm J Respir Crit Care Med19961542 pt 2S21S268756783
   PubMed Web of Science ®Google Scholar
• BüttnerCLunASplettstoesserTKunkelGRenzHMonoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functionsEur Respir J200321579980312765424
   PubMed Web of Science ®Google Scholar
• CrimiESpanevelloANeriMIndPWRossiGABrusascoVDissociation between airway inflammation and airway hyperresponsiveness in allergic asthmaAm J Respir Crit Care Med19981571499445270
   PubMed Web of Science ®Google Scholar
• BrightlingCEBraddingPSymonFAHolgateSTWardlawAJPavordIDMast-cell infiltration of airway smooth muscle in asthmaN Engl J Med2002346221699170512037149
   PubMed Web of Science ®Google Scholar
• Flood-PagePSwensonCFaifermanIInternational Mepolizumab Study GroupA study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaAm J Respir Crit Care Med2007176111062107117872493
   PubMed Web of Science ®Google Scholar
• HaldarPPavordIDNoneosinophilic asthma: a distinct clinical and pathologic phenotypeJ Allergy Clin Immunol200711951043105217472810
   PubMed Web of Science ®Google Scholar
• GibsonPGSimpsonJLSaltosNHeterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8Chest200111951329133611348936
   PubMed Web of Science ®Google Scholar
• DouwesJGibsonPPekkanenJPearceNNon-eosinophilic asthma: importance and possible mechanismsThorax200257764364812096210
   PubMed Web of Science ®Google Scholar
• PavordIDBrightlingCEWoltmannGWardlawAJNon-eosinophilic corticosteroid unresponsive asthmaLancet199935391712213221410392993
   PubMed Web of Science ®Google Scholar
• JatakanonALimSBarnesPJChanges in sputum eosinophils predict loss of asthma controlAm J Respir Crit Care Med20001611647210619799
   PubMed Web of Science ®Google Scholar
• GreenRHBrightlingCEMcKennaSAsthma exacerbations and sputum eosinophil counts: a randomised controlled trialLancet200236093471715172112480423
   PubMed Web of Science ®Google Scholar
• JayaramLPizzichiniMMCookRJDetermining asthma treatment by monitoring sputum cell counts: effect on exacerbationsEur Respir J200627348349416507847
   PubMed Web of Science ®Google Scholar
• ChlumskyJStrizITerlMVondracekJStrategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthmaJ Int Med Res200634212913916749408
   PubMed Web of Science ®Google Scholar
• HaldarPBrightlingCEHargadonBMepolizumab and exacerbations of refractory eosinophilic asthmaN Engl J Med20093601097398419264686
   PubMed Web of Science ®Google Scholar
• NairPPizzichiniMMKjarsgaardMMepolizumab for prednisone-dependent asthma with sputum eosinophiliaN Engl J Med20093601098599319264687
   PubMed Web of Science ®Google Scholar
• WellerPFThe immunobiology of eosinophilsN Engl J Med199132416111011182008184
   PubMed Web of Science ®Google Scholar
• MouldAWRamsayAJMatthaeiKIYoungIGRothenbergMEFosterPSThe effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyper-reactivityJ Immunol200016442142215010657668
   PubMed Web of Science ®Google Scholar
• HoganSPRosenbergHFMoqbelREosinophils: biological properties and role in health and diseaseClin Exp Allergy200838570975018384431
   PubMed Web of Science ®Google Scholar
• HaldarPPavordIDShawDECluster analysis and clinical asthma phenotypesAm J Respir Crit Care Med2008178321822418480428
   PubMed Web of Science ®Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet2012380984265165922901886
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJSIRIUS InvestigatorsOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• PouliquenIJKornmannOBartonSVPriceJAOrtegaHGCharacterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumabInt J Clin Pharmacol Ther201553121015102726445140
   PubMed Web of Science ®Google Scholar
• RosenbergHFPhippsSFosterPSEosinophil trafficking in allergy and asthmaJ Allergy Clin Immunol2007119613021303
   Web of Science ®Google Scholar
• SmithADCowanJOFilsellSDiagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional testsAm J Respir Crit Care Med2004169447347814644933
   PubMed Web of Science ®Google Scholar
• ParulekarADAtikMAHananiaNAPeriostin, a novel biomarker of TH2-driven asthmaCurr Opin Pulm Med2014201606524247042
   PubMed Web of Science ®Google Scholar
• OrtegaHGYanceySWMayerBSevere eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesLancet Respir Med20164754955627177493
   PubMed Web of Science ®Google Scholar
• EverittBLandauSLeeseMStahlDCluster Analysis5th edChichesterWiley Interscience2011
   Google Scholar
• MooreWCMeyersDAWenzelSENational Heart, Lung, and Blood Institute’s Severe Asthma Research ProgramIdentification of asthma phenotypes using cluster analysis in the Severe Asthma Research ProgramAm J Respir Crit Care Med2010181431532319892860
   PubMed Web of Science ®Google Scholar
• OrtegaHLiHSurukiRAlbersFGordonDYanceySCluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthmaAnn Am Thorac Soc20141171011101724983709
   PubMedGoogle Scholar
• ScottHAGibsonPGGargMLWoodLGAirway inflammation is augmented by obesity and fatty acids in asthmaEur Respir J201138359460221310876
   PubMed Web of Science ®Google Scholar
• DesaiDNewbyCSymonFAElevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthmaAm J Respir Crit Care Med2013188665766323590263
   PubMed Web of Science ®Google Scholar
• FDA [webpage on the Internet]FDA approved drug products: Nucala2015 [cited February 6, 2017]. Available from: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125526Accessed May 12, 2017
   Google Scholar
• European Medicines Agency [webpage on the Internet]European Medicines Agency – Nucala2015 [cited February 6, 2017]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003860/human_med_001933.jsp&mid=WC0b01ac058001d124Accessed May 12, 2017
   Google Scholar
• National Institute for Health and Clinical Excellence [webpage on the Internet]Mepolizumab for treating severe refractory esoinophilic asthmaTechnol Apprais Guid2016 Available from: https://www.nice.org.uk/guidance/ta431/chapter/1-RecommendationsAccessed May 12, 2017
   Google Scholar
• SurukiRYGunsoyNShinJ-YThe identification and description of severe asthma patients in a cross-sectional study-the ideal studyJ Allergy Clin Immunol20171372AB103
   Web of Science ®Google Scholar
• HaldarPBrightlingCESingapuriAOutcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysisJ Allergy Clin Immunol2014133392192324418480
   PubMed Web of Science ®Google Scholar